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Abstract
Background: The phosphatase PTEN governs the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway which is
arguably the most important pro-survival pathway in neurons. Recently, PTEN has also been implicated in multiple
important CNS functions such as neuronal differentiation, plasticity, injury and drug addiction. It has been reported
that loss of PTEN protein, accompanied by Akt activation, occurs under excitotoxic conditions (stroke) as well as in
Alzheimer’s (AD) brains. However the molecular signals and mechanism underlying PTEN loss are unknown.
Results: In this study, we investigated redox regulation of PTEN, namely S-nitrosylation, a covalent modification of
cysteine residues by nitric oxide (NO), and H2O2-mediated oxidation. We found that S-nitrosylation of PTEN was
markedly elevated in brains in the early stages of AD (MCI). Surprisingly, there was no increase in the H2O2-
mediated oxidation of PTEN, a modification common in cancer cell types, in the MCI/AD brains as compared to
normal aged control. Using several cultured neuronal models, we further demonstrate that S-nitrosylation, in
conjunction with NO-mediated enhanced ubiquitination, regulates both the lipid phosphatase activity and protein
stability of PTEN. S-nitrosylation and oxidation occur on overlapping and distinct Cys residues of PTEN. The NO
signal induces PTEN protein degradation via the ubiquitin-proteasome system (UPS) through NEDD4-1-mediated
ubiquitination.
Conclusion: This study demonstrates for the first time that NO-mediated redox regulation is the mechanism of
PTEN protein degradation, which is distinguished from the H2O2-mediated PTEN oxidation, known to only
inactivate the enzyme. This novel regulatory mechanism likely accounts for the PTEN loss observed in
neurodegeneration such as in AD, in which NO plays a critical pathophysiological role.
Background
PTEN, the phosphatase and tensin homologue deleted
on chromosome 10, is one of the most frequently
mutated tumor suppressors in human cancers. The
major, and best characterized, function of PTEN is its
lipid phosphatase activity which dephosphorylates PIP3
to generate PIP2, and thus antagonizes the PI3K activity
in the activation of Akt [1,2]. PTEN is expressed in
almost all types of neurons [3] and is critical in multiple
CNS functions such as neuronal differentiation and
synaptogenesis [3-5], neuronal plasticity [6], neuronal
injury (e.g., axonal branching/regeneration) [7,8] myelin
thickness of periphery nerves [9], and in drug
addiction [10]. Our research has focused on elucidating
novel roles for PTEN in neuronal death and neurode-
generation. We and others have reported that PTEN
protein levels are reduced in AD brains, accompanied
by elevated Akt phosphorylation [11-13]. We hypothe-
size that loss of PTEN protein is a key event regulating
the PI3-K/Akt signaling, arguably the most important
pro-survival pathway in neurons. In this study, we
aimed to investigate the underlying molecular mechan-
ism of PTEN loss.
Studies conducted in experimental models for cancer
and diabetes have shown that PTEN regulation is rather
complex. Multiple mechanisms might be involved in a
decrease or loss of PTEN function, in addition to gene
mutation and deletion. These mechanisms may include
transcription and post-translational modifications
(PTMs) which include phosphorylation, acetylation,
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stable protein but its stability can be reduced in certain
conditions, such as zinc treatment in neurons [15].
Phosphorylation at the S/T380-385 and T366/S370 sites
influences PTEN stability as well as negatively regulating
its enzymatic activity [16,17]. Besides phosphorylation,
the ubiquitin-mediated proteasomal pathway is also an
important mechanism regulating PTEN protein stability.
We recently identified NEDD4-1 as the first ubiquitin
ligase (E3) for PTEN that regulates PTEN degradation
in multiple cancer types and in neurons [15,18].
PTEN can be acutely regulated by oxidative stress and
by endogenously produced reactive oxygen species
(ROS) [19]. Oxidation of the active site cysteine
residue(s) by ROS has long been recognized as a com-
mon mechanism regulating several key members of the
protein tyrosine phosphatases (PTPs) including PTEN.
A number of ROS species, including hydrogen peroxide
(H2O2), superoxide, peroxynitrite and nitrosothiol, mod-
ify PTEN on the critical cysteine residue (C124) and
inactivate its lipid phosphatasea c t i v i t yi nm u l t i p l ec a n -
cer cell lines [20-24]. To investigate the molecular
mechanism(s) underlying PTEN loss in the brains of AD
patients, we examined these oxidative events with a spe-
cial focus on H2O2 and NO-mediated S-nitrosylation;
the later, a process of reversible addition of NO to Cys-
sulfur in proteins, has emerged as a major regulatory
mechanism in fine-tuning many critical molecules in the
neuronal death pathway and neurodegeneration [24]. To
our surprise, only NO-mediated events lead to PTEN
protein degradation, though both modifications inacti-
vate PTEN’s lipid phosphatase activity in neurons. To
our knowledge, this is the first report of NO being the
upstream signal that leads to a series of PTMs regulat-
ing PTEN protein degradation.
Results
S-nitrosylated PTEN levels are increased in MCI/AD brains,
correlating with reduced PTEN and elevated P-Akt
Initially, we sought to investigate whether S-nitrosylated
PTEN (SNO-PTEN) is produced in neurodegenerative
disorders associated with high levels of nitrosative stress
such as stroke, AD and Parkinson’sd i s e a s e( P D ) .W e
included in our tests those specimens taken from
autopsy patients diagnosed at an early stage of AD,
called mild cognitive impairment (MCI), and compared
them to aged matched control brain specimens (i.e.,
patients died from disorders not related to CNS). The
patient cohort and information are summarized in the
table [Additional file 1].
From semi-quantitative profiling of PTEN/Akt in 27
human brains, we found that SNO-PTEN was markedly
induced in the entorhinal cortices, the most vulnerable
region in AD brains, as early as the MCI stage but was
nearly undetectable in age-matched normal brains (NC)
(Figure 1A). Although the number of specimens with
matching ages is too small to conduct serious statistical
analysis, SNO-PTEN was elevated in all the Lewy body
and PD brains as examined by biotin-switch assays, sug-
gesting nitrosylation of PTEN is a common denominator
in these neurodegenerative disorders. Due to the spora-
dic nature of AD, it is not surprising that the level of
SNO-PTEN is not inversely correlated with the level of
PTEN protein in each individual case. However, statisti-
cal analysis reveals a trend (Figure 1B). Most signifi-
cantly, the P-Akt was increased in the MCI samples
compared to NC (Figure 1C) which correlates better
with the elevated SNO-PTEN but not with the reduced
PTEN protein in AD stage. Further analysis using
Pearson’s correlation analysis method revealed that
SNO-PTEN is highly positively correlated with p-Akt
level (0.8992) while PTEN level is negatively correlated
with p-Akt (-0.6387) in AD samples. The inverse corre-
lation between PTEN protein levels and P-Akt (Ser473)
appears to be more significant for AD/NC than for
M C I / N C ,s u g g e s t i n gt h a tS N O - P T E Nm a yn o tc a u s e
immediate protein degradation. However, the great var-
iation of total Akt levels among the AD samples makes
it difficult for a solid conclusion. Interestingly, the two
AD cases (indicated by black asterisks) showing the
highest levels of SNO-PTEN were also affected by cere-
bral infarcts (strokes); the two AD cases marked by red
asterisks showed very low levels or complete loss of
PTEN and low levels of Akt protein but relatively high
levels of phosphorylated P-Akt. Surprisingly, we did
not observe a significant change in the oxidative status
of PTEN between MCI and NC sample groups
(Figure 1D), as determined by a band-shift assay on
non-reducing gels as described [22,23].
PTEN can be S-nitrosylated in cultured neuronal cells by
exogenously and endogenously generated NO
Using cultured primary rat cortical neurons and biotin-
switch assays, we found that SNO-PTEN can be rapidly
induced in primary cultured cortical neurons treated
with the physiological NO donor S-nitrosocysteine
(SNOC) in a dose-dependent manner with detectable
nitrosylation achieved by as little as 10 μM SNOC and a
p l a t e a uw i t h3 0 0μM (Figure 2A). This was also con-
firmed by a more quantitative fluorescent assay (DAN
assay, Ref. [25]) using purified recombinant PTEN (Fig-
ure 2B). Additional neurotoxic compounds that induce
NO generation, such as glutamate or b-amyloid peptides
(Ab25-35) also induced robust SNO-PTEN within min-
utes (Figure 2C) and lasted for more than 10 hours,
even after the NO donors were removed from the cul-
tured media. Interestingly, the classic apoptotic stimuli,
staurosporine/STS, did not induce SNO-PTEN. Since
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2+ influx through non-
NMDAR type ion channels, our results indicate that the
source of NO induced by glutamate/Ab is most likely
via the activated nNOS in response to NMDAR-
mediated Ca
2+ influx. Two other mitochondrial ROS
agents (rotenone and MPP
+) also induced SNO-PTEN
(data not shown); this is consistent with SNO-PTEN in
PD brains and suggests that SNO-PTEN may play a
common role in chronic degenerative diseases such as
AD and PD. In parallel, we found that after treatment of
SNOC/glutamate/Ab, the majority of PTEN in neuronal
cells (>85%) remained unmodified by H2O2-type oxida-
tion, indicating that H2O2 may not be the dominant oxi-
dizing species induced by these treatments (Figure 2D).
This is consistent with one recent report [26]. Further-
more, we found that the same experimental conditions
that induced PTEN nitrosylation led to Akt activation as
assessed by increased P-Akt; both were diminished by
DTT treatment (Figure 2E).
NO signal induces subsequent enhanced ubiquitination
of PTEN, leading to protein degradation via UPS
We found reduced PTEN (>50%) steady-state levels in
neurons 2-4 h after exposure to SNOC, glutamate or
Ab25-35 peptides in a time-dependent manner (Figure
3A and 3B). Interestingly, the reduction in PTEN was
not observed after H2O2, staurosporine (STS), or oka-
daic acid (OA). The strong correlation between SNO-
PTEN formation and the reduced PTEN protein level
suggests that the PTEN decrease may be a direct conse-
quence of PTEN S-nitrosylation or may be caused
otherwise by NO signaling. Indeed, pretreatment with a
Figure 1 Quantitative analysis of PTEN and P-Akt levels in relation to SNO-PTEN in human brains. (A) SNO-PTEN levels were detected by
immunoblot analysis following biotin-switch assays. Other proteins were detected by Western blot analysis using 15 μg of brain lysate. (B)
Quantification of the Western blots using densitometry analysis reveals a statistically significant elevation of SNO-PTEN levels in MCI and AD
brains compared to NC brains *** indicates P < 0.001. (C) An inverse correlation between PTEN and p-Akt levels. * indicates P < 0.05 in MCI and
AD compared to NC brains for total PTEN levels. ** indicates P < 0.005 between AD and NC groups for P-Akt. (D) Examination of H2O2-type
oxidation of PTEN by band-shift assays: neuronal cells or brains were lysed in buffer containing 2% SDS and 40 mM N-ethylmaleimide and 20 μg
of proteins was subjected to 10% SDS-PAGE under non-reducing condition as described [22]. “Unt” stands for untreated neurons. H2O2 was used
at 100 μM for 2 h as a positive control for band-shift of the oxidized PTEN.
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Page 3 of 12NOS inhibitor (l-NMMA) or the proteasome inhibitor
MG132 for 5 h prior to glutamate exposure rescued the
decrease in PTEN by over 70%and 50%, respectively
(Figure 3C), suggesting protein degradation via the ubi-
quitin-proteasome system (UPS).
We also found that SNOC/glutamate/Ab all induce
enhanced PTEN ubiquitination with the maximum
effect seen 2 h after treatments (Figure 4A). Consistent
with enhanced ubiquitination, we found increased physi-
cal interaction between PTEN and its E3 ligase NEDD4-
1 after these treatments (Figure 4B), as we published
recently [15]. Moreover, downregulation of NEDD4-1 by
its specific siRNA prevented PTEN degradation induced
by SNOC treatment (Figure 4C). Together with the
MG132 data, these findings indicate the involvement of
the UPS in PTEN protein degradation. It is not clear
whether S-nitrosylation of PTEN itself can lead to
enhanced PTEN ubiquitination and protein degradation.
SNO-PTEN likely occurs at multiple Cys residues in the
phosphatase domain of PTEN, inactivating its lipid
phosphatase activity
We next examined the effect of PTEN S-nitrosylation
on the lipid phosphatase activity of PTEN. By conven-
tional Malachite Green assay using PIP3 as substrate [2],
SNOC treatment inactivated PTEN in a dose-dependent
manner with 80% of activity lost at 400 μM, which was
reversed by DTT (Figure 5). To determine the target
Figure 2 PTEN is S-nitrosylated by various chemical and biological NO donors in cultured neurons. (A) PTEN nitrosylation by SNOC in a
dose-dependent manner as detected by biotin-switch assays: to detect S-nitrosylated cystein residues, the cysteine residues of PTEN was first
masked by methylthiolation with MMTS. Nitrosothiols were then selectively reduced by ascorbate to reform free thiol group, which reacted with
biotin-HPDH. In this experiment MMTS was added to serve as a positive control since all the cysteine residues in PTEN can react with biotin-
HPDP. On the contrary, ascorbte in the untreated samples were used as negative control due to no reactive cysteine residues to biotin-HPDH.
(B) Specificity of PTEN S-nitrosylation by DAN assay. (C) PTEN can be S-nitrosylated in cultured neurons by SNOC (200 μM, 30 min), glutamate
(200 μM, 30 min), Ab peptides (10 μM, 4 h) but not by staurosporine (STS, 200 nM, 30 min). (D) H2O2-induced oxidation in primary neurons with
the same treatment conditions as in (C). H2O2 was used at 100 μM for 2 h. (E) P-Akt was detected by Western blot analysis 30 min after
treatments with SNOC (200 μM), glutamate (200 μM), Ab peptides (10 μM) in neurons. For the right panel, 10 mM DTT was added during the 30
min treatments.
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Page 4 of 12Figure 3 PTEN S-nitrosylation correlates with protein degradation. (A) Effects of various neurotoxins on the steady-state protein level of
PTEN 4 h after treatments. N = 6 experiments. (B) Cycloheximide-chase experiment on PTEN stability. PRCN cells were incubated with 50 μg/ml
cycloheximide (CHX) for the indicated times in the presence or absence of glutamate (200 μM). Cells were simultaneously treated with
glutamate and cycloheximide. Two groups of neurons were also co-treated with glutamate and 25 μM MG132. Cells lysates were then prepared
for Western blot analysis of steady-state levels of PTEN. (C) Glutamate-induced reduction of PTEN can be rescued by l-NMMA (1 mM) and MG132
(25 μM) pretreatment for 5 and 1 h, respectively, as examined by three independent experiments.
Figure 4 NO signals induce enhanced ubiquitination of PTEN, leading to protein degradation. (A) Treatments with SNOC, glutamate or
Ab peptides increase PTEN ubiquitination, as determined by IP-Western analysis. (B) Enhanced physical interaction between PTEN and NEDD4-1
upon various treatments at the conditions used in other experiments, as determined by co-immunoprecipitation/Western blot analysis. Figure is
chosen as the representative of three independent experiments. (C) Downregulation of NEDD4-1 by siRNA ( 4 μg) prevents PTEN protein
degradation upon SNOC treatment.
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Page 5 of 12site(s) of SNOC on PTEN, we performed site-directed
mutagenesis on each of the 10 cysteine residues (Cys to
Ala replacement) (Figure 6A). Using biotin-switch
assays, we examined the nitrosylation levels of each
PTEN mutant after transfection into mouse neuroblas-
toma N2a cells 30 min after exposure to 200 μM SNOC
and compared SNO-PTEN levels to those of WT PTEN.
For the 10 PTEN mutants, only Cys83A mutant dis-
played significantly reduced S-nitrosylation [75% reduc-
tion based on the mean values of 7 experiments,
Figure 6B and also see additional file 2]. Thus, the most
likely candidate cysteine residue that is physiologically
S-nitrosylated is C83. The C71A and C124A mutations
only partially affected S-nitrosylation (~25%), and the
double mutant C71C83A was nitrosylated similarly to
the C83A mutant. The C71C124A double mutant had
the same effect as single mutants. In contrast, triple
mutant C71C83C124A completely abolished the PTEN
nitrosylation, suggesting an involvement of all three Cys
residues to varying degrees under our conditions.
Furthermore, we also observed greatly reduced ubiquiti-
nation for the triple mutant (Figure 6C) which suggests
the possibility that its ubiquitination may be partially
dependent on PTEN nitrosylation. Interestingly, the
steady-state levels of the triple mutant was not reduced
by SNOC treatment as compared to WT or C71C83
double mutant [see additional file 3], indicating that the
C124 residue is a critical determinant for PTEN protein
stability.
Downregulation of PTEN and elevated P-Akt levels
protect neurons against Ab-induced toxicity
In cultured primary neurons, exposure to Ab or NMDA
induced a rapid decrease in PTEN and increase in
P-Akt levels. Downregulation of endogenous PTEN via
specific siRNA produces neuroprotection, as evidenced
by preserved neuronal structures (Figure 7A and 7B;
MAP2/NeuN staining/Green). Moreover, the frontal
region of the brain of PTEN heterozygous mice bear
reduced PTEN as compared to WT littermate controls
(~50% reduction) and increased basal P-Akt levels (Fig-
ure 7C). Cortical neurons from PTEN+/- brains exhib-
ited increased resistance to Ab-induced cell death
compared to those from WT littermate controls (Figure
7D), suggesting a neuroprotective role for PTEN
downregulation.
Discussion
PI3K/Akt is arguably the most important cell-survival
signaling pathway for neurons. As the key negative
regulator of the PI3K/Akt pathway, PTEN is an impor-
tant target of study for neuroprotection during neuro-
degeneration. In this work, we are the first to
demonstrate NO-mediated redox regulation as the
mechanism of PTEN protein degradation. We also
demonstrate that NO rapidly induces S-nitrosylation of
PTEN, thereby inactivating i t .M o r e o v e r ,N O ,b u tn o t
H2O2, induces PTEN protein degradation. Loss of
PTEN protein is reportedly associated with myocardial
and brain ischemia [27-29], presumably as a cellular
adaptive stress response to activate the pro-survival
PI3K/Akt signaling. Herein, we show that PTEN loss
also occurs in neurons in response to a variety of neu-
rotoxins (e.g., glutamate and Ab peptides) as well as in
chronic neurodegenerative conditions such as AD and
PD brains. Hence, our findings on NO-mediated PTEN
protein degradation may represent a common mechan-
ism underlying PTEN loss in these acute and chronic
degenerative conditions, in which NO plays a critical
pathophysiological role.
Figure 5 SNOC treatment inactivates PTEN’s lipid phosphatase activity. (A) Dose-dependent effect of SNOC on lipid phosphatase activity as
determined by Malachite Green assay. Data presented are means based on five independent experiments. ** indicates p < 0.05 and *** indicates
p < 0.005. (B) DTT treatment (10 mM) completely restores the PTEN’s lipid phosphatase activity abolished by SNOC (300 μM).
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earliest changes that occurs in the pathogenesis of AD,
arising from the imbalance between increased produc-
tion of reactive oxygen and nitrogen species and
impaired antioxidant defenses, as reflected in the accu-
mulation of oxidative damage to macromolecules
detected in MCI, the clinical precursor of AD, and AD
brains [30,31]. H2O2-induced modification and S-nitro-
sylation represent the two dominant oxidative events
through targeted modifications of critical Cys residues
in proteins. H2O2-induced PTEN oxidation was reported
to cause the formation of an intra-chain disulfide bond
between C71-124 [22], and is reflected in faster mobility
species by band-shift assay on non-reducing gels (Figure
2D). SNOC did not induce a band shift of PTEN on
non-denaturing gels and thus unlikely induced a major
conformational change due to intra-chain disulfide bond
formation. However, our mutagenesis data suggest the
involvement of overlapping residues on C71 and C124.
It is, therefore, reasonable to predict that these two oxi-
dative modifications can compete with each other when
both oxygen and NO species are present. Moreover, our
data indicate that NO-mediated oxidation is the predo-
minant form of PTEN in aging brains and in MCI/AD
brains (Figure 1D), which may generalize to other neu-
rodegenerative diseases such as PD.
Although our mutagenesis studies (Figure 6B) cannot
determine the nitrosylated sites unambiguously, the
results strongly suggest that C83 is likely the most sig-
nificant physiological site of S-nitrosylation on PTEN. It
is possible that multiple Cys residues are involved
depending on the spatial and temporal concentrations of
NO. It is well known that the C124 residue is critical for
the enzymatic activity of PTEN [32]; mutation of this
residue results in inactivation of both the protein and
phospholipid lipase activities of PTEN. Our data [see
Figure 6 Mapping the SNO-PTEN sites by site-directed mutagenesis. (A) (Top scheme) Structural domains of PTEN: phosphatase domain,
Ca-independent C2 and a PDZ binding domain at the C-terminus. (B) SNO-PTEN levels of Cys to Ala mutants as measured by biotin switch
assays. Transfected N2a cells were treated with 200 μM SNOC for 30 min before cells were harvested for biochemical analysis. Data presented
here is representative of 7 experiments. (C) PTEN ubiquitination as measured by IP-Western. Transfected WT or triple mutant PTEN were IPed
with anti-HA antibody and immunoprobed with an antibody against ubiquitin. (D) Protein structure of the lipid phosphatase domain with three
putative Cys residues labeled based on published PTEN crystal data [32].
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protein stability; mutation on this Cys residue renders
PTEN resistance to SNOC-induced protein degradation.
It warrants further investigation of the underlying
mechanisms. Structural analysis based on the solved
crystal structure of PTEN [33] indicates that Cys83 is
not in close vicinity to C124, which is located face-to-
face to C71 (Figure 6D). It is therefore not yet clear
mechanistically how C83, in conjunction with C71 and
C124, affects the lipid phosphatase activity of PTEN.
Our results demonstrate NO-mediated PTEN protein
degradation via UPS, as evidenced by enhanced ubiquiti-
nation. There are several precedents showing that pro-
tein S-nitrosylation can be functionally coupled to its
ubiquitination and modulate protein degradation
[34-38]. It is possible that S-nitrosylation of PTEN plays
a direct causative role in its degradation, as evidenced
by enhanced ubiquitination upon SNOC treatment (Fig-
ure 4A). Given the role of phosphorylation in modulat-
ing PTEN protein stability and activity previously
revealed by cancer cell models [14,38], it is also possible
that NO signal induces alteration on PTEN phosphory-
lation status which is the cause of enhanced ubiquitina-
tion and protein degradation. Interestingly, the two
putative kinases identified as responsible for phosphory-
lation of the two major clusters on PTEN (Ser/Thr clus-
ter 380/382/383 and Thr366/Ser370), namely glycogen
synthase kinase GSK3b and casein kinase CK2, are both
Figure 7 Down regulation of PTEN is neuroprotective in acute experimental models. (A) and (B) Downregulation of PTEN with specific
siRNA confers neuroprotection 24 h after Ab exposure (25 μM): PTEN IHC staining (red, A) and MAP/NeuN staining for neuron morphology
(green, B). (C) Reduced PTEN protein level in PTEN heterozygous mouse brain (frontal region), accompanied by elevated P-Akt level (2-month-old
mice, n = 2). (D) Primary cultured cortical neurons from PTEN +/- pups manifest less apoptotic cell death than PTEN+/+ neurons 24 h after Ab
exposure. Data presented as means ± SD from 5 independent experiments.
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unpublished data show that OA can prevent PTEN
dephosphorylation to a significant extent following
exposure to SNOC, suggesting that PP2A, PP1 and per-
haps PP2B, all major protein phosphatases implicated in
AD [41], may play a role in modulating PTEN stability.
Thus, the detailed interplay between kinases and phos-
phatases warrants further investigation.
Although we made our initial observation in MCI/AD
brain samples, the loss of PTEN is also reported to
occur in both myocardial [27] and cerebral ischemia/
reperfusion [28,29]. Therefore, we believe that PTEN
inhibition in these acute conditions mediates subsequent
activation of PI3K/Akt signaling, which is known to be
key to the endogenous protective effect, similar to the
neuronal adaptive response. Paradoxically, we found that
loss of PTEN occurs in human brains with AD, accom-
panied by elevated P-Akt in AD-affected regions. More-
over, the elevated P-Akt has often been detected in the
same neuron bearing neurofibrillary tangles, which is a
major pathological hallmark of AD consisting of hyper-
phosphorylated tau protein [13]. Although a reduction
of P-Akt was also reported by previous studies [42]; we
repeatedly found elevated P-Akt levels in degenerating
neurons in AD brains by immunohistochemistry
(unpublished data), which is consistent with several
other reports [11,43]. Taken with our earlier finding
that downregulated PTEN resulted in tau hyperpho-
sphorylation and aggregation, we speculate that the loss
of PTEN may be a contributing factor to neurodegen-
eration over the course of the disease due to chronically
or excessively activated Akt signaling, which we specu-
late to be detrimental, as has been reported in several
other chronic diseases [44,45]. Akt is activated in sam-
ples from patients with chronic heart failure; biochem-
ical analyses demonstrated that chronic Akt activation
induces feedback inhibition [46]. This nascent theory
appears to be supported by a finding that conditional
PTEN ablation in the forebrain region which caused
impaired synaptic structure and function with concomi-
tant constitutive activation of Akt and mTOR signaling
[47]. An alternative view would be that the increase in
Akt signaling occurs in response to damage, as an adap-
tive response, but fails to reach significantly protective
levels under these chronic conditions. Only future
experiments will be able to distinguish between these
alternatives.
Conclusions
In summary, our studies have demonstrated that
S-nitrosylation of PTEN plays a major role in PTEN
regulation in neuronal systems and that NO signaling
induces S-nitrosylation and ubiquitination to modulate
both PTEN protein degradation and enzymatic activity,
which may represent the underlying regulatory mechan-
ism of the PI3K/Akt signaling pathway in both acute
and chronic neurodegeneration. A fuller understanding
of the molecular mechanisms underlying the cascade of
events leading to PTEN inhibition in both acute and
chronic settings will advance our knowledge of PTEN
regulation in the CNS. It may also be instrumental in
future therapeutic design of novel target-based interven-
tion in treating neurodegenerative diseases and perhaps
other age-related conditions such as cancers, diabetes,
cardiovascular ischemia and stroke.
Methods
Cell culture, treatment of neurotoxic reagents
and transfection
Primary cultured cortical neurons (PRCN) and neuro-
blastoma N2a cells were prepared as described [48]. For
the majority of experiments, freshly prepared SNOC
(Sigma-Aldrich, St. Louis, MO) was added at 200 μMt o
2-week-old cultured neurons for 30 min. SNOC was
freshly prepared as described [49]. In brief, to prepare a
100 mM stock solution, 0.0069 g sodium nitrite and
0.0121 g l-cysteine were added to 950 μlH 2O. Then,
50 μl of 10 N HCl is added to adjust pH to be 7.4. For
glutamate (Sigma-Aldrich), Ab25-35 peptides (Bachem,
Torrance, CA), and staurosporine/STS (Sigma-Aldrich),
neurons were treated for 4 hours before cell lysates
were prepared. For suppression of NOS activity,
l-NMMA (Sigma-Aldrich, 1 mM) was applied to neu-
rons before exposure to neurotoxic reagents.
Transient transfections were performed with plasmid
constructs for pEF-PTEN-WT (kindly provided by Dr.
Hong Wu, UCLA, CA) and its site-directed mutagenized
constructs (Cysteine to Alanine substitution).
Human patient brains
Human brain samples were provided by UCSD, San
Diego, CA and were analyzed with institutional permis-
sion under California and National Institutes of Health
guidelines. Informed consent was obtained following the
procedures of the Institutional Review Boards of the
Sanford-Burnham Institute for Medical Research.
Biotin-switch assay for detection of PTEN S-nitrosylation
A biotin switch assay for detection of SNO-PTEN was
performed as previously described with minor modifica-
tion [50]. PRCN cultures were exposed to various con-
centrations (10, 50, 100, 200 and 300 μM) of SNOC
and old SNOC for 30 min, glutamate, STS, or Ab25-35
for 4 h.
Fluorometric measurement of S-nitrosylation of PTEN
S-nitrosylation of PTEN was measured as previously
described [25].
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Cells were lysed in buffer containing 2% SDS and 40
mM N-ethylmaleimide and 20 μgo fp r o t e i nw a ss u b -
jected to 10% SDS-PAGE under non-reducing condition
as described [22,23].
PTEN phosphatase assay-Malachite green assay
Recombinant PTEN, which was expressed in baculo-
virus, was assessed for the phosphatase activity as pre-
viously described [2]. Enzymatic activity of PTEN was
quantified as activity measured relative to the control.
Immunoprecipitation and Western blot analysis
IP-Western experiments were performed as described
[48]. The following antibodies (Abs) were used: rabbit
anti-PTEN Ab (Cell Signaling, Danvers, MA, USA); goat
anti-PTEN (Santa Cruz, Santa Cruz, CA); mouse anti-a-
tubulin Ab (Sigma, St. Louis, MO, USA); rabbit anti-P-
Akt Ab (Cell Signaling, Danvers, MA, USA); rabbit Akt
1 / 2 / 3( S a n t aC r u z ,S a n t aC r u z ,C A ) ;m o u s ea n t i - m o n o -
poly-Ub Ab (Enzo, Plymouth Meeting, PA); rabbit anti-
NEDD4 Ab (Upstate, Charlottesville. VA, USA); mouse
anti-b-actin Ab (Sigma); anti-mouse IgG and anti-rabbit
IgG horseradish peroxidase-conjugated Abs (Chemicon,
Temecula, CA, USA).
Cycloheximide chase assay
PRCN cells were incubated with 50 μg/ml cyclohexi-
mide (Sigma, St. Louis, MO, USA) for the indicated
times in the presence or absence of glutamate (200
μM). Cells were simultaneously treated with glutamate
and cycloheximide. To examine whether the UPS is
involved in nitrosative stress induced PTEN reduction,
cells were co-treated with glutamate and 25 μM
MG132. Cells lysates were then prepared for Western
blot analysis.
Sindbis virus-delivered RNA interference mediated
silencing of PTEN in PRCN
Three different sets of siRNAs were designed by
Ambion for rat PTEN (RefSeq NM_031606, Ambion).
The annealed oligonucleotides encoding siRNAs were
cloned into the pIRES-enhanced RFP (Invitrogen)
using EcoRI/BamHI sites and the resulting siRNA-
IRES-RFP fragment was further cloned into pSin-
Rep5 (Invitrogen). The efficiency and specificity of
PTEN-siRNAs were then assessed by RT-PCR and
western blot analysis. Virus particles were generated
and infection performed in primary neurons accord-
ing to the manufacturer’s protocol as described pre-
viously [13].
Site-directed mutagenesis of PTEN
PTEN mutants were created by site-directed mutagen-
esis (QuikChange® II Site-Directed Mutagenesis Kits,
Stratagene, La Jolla USA) at C71, C83, C105, C124,
C136, C211, C218, C250, C296, C304, and its double/
triple mutants with various combinations. The primers
for C71A forward 5’-TTTAAAGCATAAAAACCATTA
CAAGATATACAA-3’ and reverse 5’-GTCATAATGTC
TAGCAGCAAGATTGTATAT-3’;C 8 3 Af o r w a r d5 ’-
GACACCGCCAAATTTAATGCCAGAGTTGCACAA-
3’ and reverse 5’-GATATTGTGCAACTCTGGCAT
TAATGGCGG-3’; C105A forward 5’-GAACTTAT
CAAACCCTTTGCTGAAGATCTTGAC-3’ and reverse
5’-CCATTGGTCAAGATCTTCAGCAAAGGGTTTG
AT-3’; C124A forward 5’-CATGTTGCAATTCACGCT
AAAGCTGGAAAG-3’ and reverse 5’-GTCCCTTT
CCAGCTTTGCGTGAATTGCTGGAATTGCTGCAA-
3’; C136A forward 5’-GACGAACTGGTGTAATGA
TAGCCGCATATTTAT-3’ and reverse 5’-CCCGATGA
TATAAATATGCGGCTATCATTACAC-3’; C211A for-
ward 5’-GTTCAGTGGCGGAACTGCCAATCCTCA
GTTTG-3’ and reverse 5’-CACAAACTGAGGATT-
GGCAGTTCCGCCACTGAA-3’; C218A forward 5’-
CCTCAGTTTGTGGTCGCCCAGCTAAAGGTGAA-3’
and reverse 5’-CTTCACCTTTAGCTGGGCGACCAC
AAACTGAGC-3’; C250A forward 5’-CAGCCGTTA
CCTGTGGCTGGTGATATCAAAG-3’ and reverse 5’-
CTTTGATATCACCAGCCACAGGTAACGGCTG-3’;
C296A forward 5’-TCAGAAAAAGTAGAAAATGG
AAGTCTAGCTGAT-3’ and reverse 5’-CAAATGCTA
TGGATTTCTTGATCAGCTAGACTT-3’; C304A for-
ward 5’- CAAGAAATCAGCATTGCCAGTATAGA
GCGT-3’ and reverse 5’-CTGCACGCTCTATACTGG
CAATGCTATCGATTT-3’ were utilized for PCR amplifi-
cation, respectively. PCR amplification was performed
according to the company’s protocol. Once single mutants
were constructed, we used these mutants as a template for
further construction of double/triple mutants.
Immunocytochemistry for neuronal morphology/dendritic
structure and cell death (TUNEL) assays
IHC on PTEN (1:500) and MAP-2/NeuN (1:500/each)
and apoptotic staining were performed as described [48]
on two week-cultured neurons seeded on glass cover
slips. In PTEN heterozygous mice were genotyped as
described [51].
Statistics
All quantitative data were presented as means ± SDV.
Comparison between groups were analyzed with
unpaired ANOVA using Graphpad PRIZM software (La
Kwak et al. Molecular Neurodegeneration 2010, 5:49
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Page 10 of 12Jolla, CA, USA) and values of p <0 . 0 5w e r ec o n s i d e r e d
to be significant.
Additional material
Additional file 1: The table of the patient brain information.
Additional file 2: Additional data on the Cys mutants. SNO-PTEN
levels were determined by biotin-switch assays and data were analyzed
by densitometry of the SNO-PTEN/total PTEN ratio, indicating that the
majority of C211-304 located in the C2 domain do not seem to be the
direct sites of S-nitrosylation.
Additional file 3: Effect of double and triple Cys mutants on PTEN
protein stability upon SNOC treatment. Various mutant plasmids were
transiently introduced to N2a cells along with WT control and cells were
treated with SNOC (200 μM) 48 h after transfection. The steady-state
levels of PTEN were determined at various time points by Western blot
analysis using anti-HA antibody to probe on the exogenously expressed
PTEN.
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